EPRX Eupraxia Pharmaceuticals Inc.

NASDAQ
$7.34

Eupraxia Pharmaceuticals Inc. (EPRX) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.27 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -7.7% since its last earnings release on November 10, 2026.

Eupraxia Pharmaceuticals Beat Consensus Estimates
Tuesday, November 10, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 5:20 PM ET
Earnings Whisper
-
vs ($0.27)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.84

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.